Method and apparatus for indicating the absence of a pulmonary embolism in a patient

• US 8,479,731 B2
• Filed: 12/02/2005
• Issued: 07/09/2013
• Est. Priority Date: 12/02/2005
• Status: Active Grant

• Current Assignee: General Electric Company
• Original Assignee: General Electric Company
• Inventors: Heinonen, Erkki, Coffeng, Rene, Verschuren, Franck
• Primary Examiner(s): Bianco, Patricia
• Assistant Examiner(s): PATEL, NIHIR B
• Application Number:
  US11/292,957
• Publication Number:
  US 20070129646A1
• Time in Patent Office: 2,776 Days
• Field of Search: 128/200.26, 128/204.22, 128/204.23, 128/200.15, 128/204.21, 128/205.23, 128/920, 600/529, 600/532, 600/301, 600/309, 600/310, 600/322, 600/364
• US Class Current: 128/204.22
• CPC Class Codes: A61B 5/0836 Measuring rate of CO2 production

Abstract

A method and apparatus for determining the presence or absence of a pulmonary embolism (PE) in a patient. The breathing gas CO₂ partial pressure (PCO₂) during the expiration of breathing gases by the patient, the end tidal (EtCO₂), CO₂ partial pressure, and the CO₂ partial pressure (PaCO₂) of the blood are measured. The volume (V) of breathing gases expired during the expiration of breathing gases by the patient is also measured and a relationship between changes in breathing gas CO₂ partial pressure (PCO₂) and changes in breathing gas volume (V) in an alveolar expiration phase of patient expiration is determined. The difference between the blood CO₂ partial pressure (PaCO₂) and the end expiration CO₂ partial pressure is divided by the relationship between PCO₂ and V produce a quantity which is compared to a threshold value. If the quantity is below the threshold value, the absence of a pulmonary embolism is indicated.

Claims

1. A method for determining the presence or absence of a pulmonary embolism in a patient, said method comprising the steps of:

(a) measuring the amount of CO₂ expired by the patient during the expiration of breathing gases by the patient using a breathing gas CO₂ concentration sensor;

(b) measuring the volume (V) of breathing gases expired during the expiration of breathing gases by the patient using a flow sensor;

(c) determining a slope in a measurement apparatus, the slope defined by a change in the amount of expired CO₂ divided by a change in breathing gas volume in an alveolar expiration phase of patient expiration;

(d) measuring an amount of CO₂ in the lungs of the patient at the end of expiration using the breathing gas CO₂ concentration sensor;

(e) measuring the amount of CO₂ in the blood of the patient;

(f) determining the difference in the measurement apparatus between the amount of CO₂ in the blood and the amount of CO₂ in the lungs of the patient at the end of expiration;

(g) establishing a relationship in the measurement apparatus between the determination of step (f) and the determination of step (c) to produce a quantity for use in determining the presence or absence of a pulmonary embolism in the patient, and

(h) defining the alveolar expiration phase of patient expiration as that in which the quantity produced in step (c) is reduced to a given percentage of a corresponding quantity produced for a previous phase of expiration.

2. The method according to claim 1 further including a step of establishing a threshold value for the quantity produced in step (g) and indicating the presence or absence of a pulmonary embolism by the relationship of the quantity to the threshold value.

3. The method according to claim 2 further defined as indicating the presence of a pulmonary embolism when the quantity produced in step (g) is below the threshold value.

4. The method according to claim 3 wherein the threshold value is expressed in milliliters and wherein the threshold value is 250 mL or greater.

5. The method according to claim 4 wherein the threshold value is between 250 and 300 mL.

6. The method according to claim 3 wherein an indication of the absence of PE is made when the quantity produced in step (g) is below a quantity comprising the threshold value less a margin of error.

7. The method according to claim 1 wherein step (g) is further defined as dividing the determination of step (f) by the determination of step (c) to produce the quantity.

8. The method according to claim 7 further including a step of establishing a threshold value for the quantity produced in step (g) and indicating the presence or absence of a pulmonary embolism by the relationship of the quantity to the threshold value.

9. The method according to claim 8 further defined as indicating the presence of a pulmonary embolism when the quantity produced in step (g) is below the threshold value.

10. The method according to claim 9 wherein the threshold value is expressed in milliliters and wherein the threshold value is 250 mL or greater.

11. The method according to claim 10 wherein the threshold value is between 250 and 300 mL.

12. The method according to claim 9 wherein an indication of the absence of PE is made when the quantity produced in step (g) is below a quantity comprising the threshold value less a margin of error.

13. The method according to claim 1 wherein the measurements of CO₂ amounts are expressed as CO₂ partial pressures.

14. The method according to claim 13 wherein step (d) is further defined as measuring the CO₂ partial pressure of the breathing gases of the patient at the end of expiration.

15. The method according to claim 13 wherein the measurement of CO₂ in step (e) is arterial blood CO₂ (PaCO₂).

16. The method according to claim 15 wherein the measurement of CO₂ in the arterial blood of the patient is compensated for the effect of shunt perfusion in the lungs of the subject.

17. The method according to claim 1 wherein the step of defining the alveolar expiration phase is further defined as defining the alveolar expiration phase as that in which the quantity produced in step (c) is 10-20% of the corresponding quantity produced for the previous phase of expiration.

18. The method according to claim 17 wherein the step of defining the alveolar expiration phase is further defined as defining the alveolar expiration phase as that in which the quantity produced in step (g) is 15% of the corresponding quantity produced for the previous expiration phase.

19. The method of claim 1 wherein the step of defining the alveolar expiration phase is further defined as using a combination of criteria relating to the quantity produced in step (c) and to the expiration volume.

20. The method according to claim 1 further including the step of preventing a determination of PE diagnosis if the quantity produced in step (c) does not meet a magnitude reduction criterion.

21. A method for determining the presence or absence of a pulmonary embolism in a patient, said method comprising the steps of:

(a) measuring the amount of CO₂ expired by the patient during the expiration of breathing gases by the patient using a breathing gas CO₂ concentration sensor;

(b) measuring the volume (V) of breathing gases expired during the expiration of breathing gases by the patient using a flow sensor;

(c) determining a slope in a measurement apparatus, the slope defined by a change in the amount of expired CO₂ divided by a change in breathing gas volume in an alveolar expiration phase of patient expiration;

(d) measuring an amount of CO₂ in the lungs of the patient at the end of expiration using the breathing gas CO₂ concentration sensor;

(e) measuring the amount of CO₂ in the blood of the patient;

(f) determining the difference in the measurement apparatus between the amount of CO₂ in the blood and the amount of CO₂ in the lungs of the patient at the end of expiration;

(g) establishing a relationship in the measurement apparatus between the determination of step (f) and the determination of step (c) to produce a quantity for use in determining the presence or absence of a pulmonary embolism in the patient; and

(h) defining the alveolar expiration phase as the concluding 10%-20% of the expiration volume.

22. A method for determining the presence or absence of a pulmonary embolism in a patient, said method comprising the steps of:

(a) measuring the amount of CO₂ expired by the patient during the expiration of breathing gases by the patient using a breathing gas CO₂ concentration sensor;

(b) measuring the volume (V) of breathing gases expired during the expiration of breathing gases by the patient using a flow sensor;

(c) determining a slope in a measurement apparatus, the slope defined by a change in the amount of expired CO₂ divided by a change in breathing gas volume in an alveolar expiration phase of patient expiration;

(d) measuring an amount of CO₂ in the lungs of the patient at the end of expiration using the breathing gas CO₂ concentration sensor;

(e) measuring the amount of CO₂ in the blood of the patient;

(f) determining the difference in the measurement apparatus between the amount of CO₂ in the blood and the amount of CO₂ in the lungs of the patient at the end of expiration;

(g) establishing a relationship in the measurement apparatus between the determination of step (f) and the determination of step (c) to produce a quantity for use in determining the presence or absence of a pulmonary embolism in the patient;

(h) measuring the O₂ partial pressure (EtO₂) of the breathing gases at the end of expiration;

(i) measuring the O₂ partial pressure (PaO₂) in the blood of the patient;

(j) comparing EtO₂ and PaO₂; and

(k) precluding an indication of the absence of a pulmonary embolism if the O₂ difference exceeds a predetermined value.